Last reviewed · How we verify

NCT03902301: ProjectPCOS

Lactobacillus Rhamnosus and PCOS Treatment

Completed NA Last updated 26 April 2022
What this trial tests

NA trial testing Lactobacillus group in Insulin Resistance in 80 participants. Completed in 31 December 2020.

Timeline
1 April 2018
Primary endpoint
31 December 2020
31 December 2020

Quick facts

Lead sponsorPoznan University of Life Sciences
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment80
Start date1 April 2018
Primary completion31 December 2020
Estimated completion31 December 2020
Sites1 location across Poland

Drugs / interventions tested

Conditions studied

Sponsor

Poznan University of Life Sciences

Who can join

Adults 18 to 40, female only, with Insulin Resistance or Polycystic Ovary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The effect of Lactobacillus rhamnosus supplementation on body weight, hyperandrogenism and insulin resistance in overweight and obesity women with Polycystic Ovary Syndrome will be analysed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Insulin Resistance

Currently open trials in the same condition.

Other Poznan University of Life Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03902301.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing